Ex–hospital porter a neglected giant of cancer researchMay 11, 2022B Cell LymphomaCLLDLBCLMantle Cell Lymphoma
100 coauthored papers, 10 years: Cancer transplant pioneers model 'team science'January 21, 2022DLBCLCLLB Cell Lymphoma
Rituximab and COVID-19 vaccines: Studies begin to answer key questionsJanuary 21, 2022CLLB Cell LymphomaDLBCL
DKMS: Small nonprofit to world’s largest stem cell donor registryJanuary 21, 2022DLBCLB Cell Lymphoma
‘Outstanding data’: Mosunetuzumab in r/r follicular lymphomaDecember 11, 2021B Cell LymphomaFollicular Lymphoma
In some lymphomas, ibrutinib yields “almost unheard-of” survival ratesDecember 8, 2021DLBCLB Cell Lymphoma
Easing access to DLBCL treatments: Patient study reveals racial differencesNovember 17, 2021DLBCLB Cell Lymphoma
New trials in lymphoma and MM: Could your patient benefit?November 10, 2021DLBCLMantle Cell LymphomaB Cell Lymphoma
BTKi resistance: ‘Achilles’ heel’ in effective treatment of B-cell malignanciesOctober 15, 2021CLLB Cell Lymphoma
FDA grants zanubrutinib an accelerated approval in marginal zone lymphomaSeptember 16, 2021B Cell Lymphoma
